Blood pressure: at what level is treatment worthwhile? [Correction]
- Aust Prescr 2019;42:175
- 1 October 2019
- DOI: 10.18773/austprescr.2019.062
A conflict-of-interest declaration, received after the original article was published, was received for Vlado Perkovic. It reads:
Vlado Perkovic has served on steering committees, advisory boards, or given scientific presentations supported by Abbvie, Astellas, Astra Zeneca, Bayer, Baxter, MBS, Boehringer Ingelheim, Dimerix, Durect, Eli Lilly, Gilead, GSK, Janssen, Merck, Metavant, Mitsubishi Tanabe, Mundipharma, Novartis, Novo Nordisk, Pfizer, Pharmalink, Relypsa, Retrophin, Sanofi, Servier, Vifor and Tricida.